Cell Signaling Technology
XP Monoclonal Antibody

Product Pathways - Glucose Metabolism

FABP4 (D25B3) XP® Rabbit mAb #3544

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IF-IC M (H) Endogenous 15 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

FABP4 (D25B3) XP® Rabbit mAb detects endogenous levels of total FABP4 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the sequence of human FABP4.

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3 and 3T3-L1 cells using FABP4 (D25B3) XP® Rabbit mAb.

IF-IC

IF-IC

Confocal immunofluorescent analysis of differentiated 3T3-L1 cells (left) and undifferentiated 3T3-L1 cells (right), using FABP4 (D25B3) XP® Rabbit mAb (red). Lipid droplets have been labeled with BODIPY 493/503 (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Background

Fatty acid binding proteins (FABPs) bind to fatty acids and other lipids to function as cytoplasmic lipid chaperones (1). They participate in the transport of fatty acids and other lipids to various cellular pathways (2). The predominant fatty acid binding protein found in adipocytes is FABP4, also called adipocyte fatty acid binding protein or aP2. FABP4 is also expressed in macrophages (3). FABP4 knockout mice fed a high-fat and high-calorie diet become obese but develop neither insulin resistance nor diabetes, suggesting that this protein might be a link between obesity and insulin resistance and diabetes (4). Mice deficient in both FABP4 and ApoE show protection against atherosclerosis when compared with mice deficient only in ApoE (3). Mice carrying a FABP4 genetic variant exhibit both reduced FABP4 expression and a reduced potential for developing type 2 diabetes and coronary heart disease. A related study in humans indicated a similar pattern, suggesting that FABP4 may be a potential therapeutic target in the treatment of these disorders (1).

  1. Tuncman, G. et al. (2006) Proc. Natl. Acad. Sci. USA 103, 6970-6975.
  2. Haunerland, N.H. and Spener, F. (2004) Prog. Lipid Res. 43, 328-349.
  3. Makowski, L. et al. (2001) Nat. Med. 7, 699-705.
  4. Hotamisligil, G.S. et al. (1996) Science 274, 1377-1379.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products